Takeda: Carcinoma trials

The registry lists 11 Carcinoma studies with Takeda as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 1Phase 2 7Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Survey of Cabozantinib Used To Treat People With Renal Cell CarcinomaCompletedNCT04804813Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular CarcinomaCompletedNCT03586973Phase 2Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell CarcinomaCompletedNCT03339219Phase 2Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedNCT02724020Phase 2Results posted
• MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase CTerminatedNCT02391038Phase 1Results posted
• Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal CarcinomaCompletedNCT02337946Phase 2Results posted
• Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerCompletedNCT01091428Phase 2Results posted
• MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedNCT00853307Phase 2Results posted
• An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT02784158
• Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaCompletedNCT00051987Phase 2